Health

Cognito Therapeutics Audiovisual Device Shows Mixed Trial Results

The largest clinical trial to date evaluating a headset device designed to slow Alzheimer’s progression has yielded mixed results, leaving the treatment’s overall efficacy under scrutiny. The study, which utilized a device that delivers flickering light and sound, was presented Monday at a major Alzheimer’s conference.

The underlying theory behind the system, known as Spectris, is that audiovisual stimulation can trigger brainwave responses, potentially preserving neurological function and assisting in the clearance of brain waste. The prospect of such a non-drug alternative has attracted interest, as it could offer an accessible option compared to existing Alzheimer’s medications, which are often expensive and associated with significant safety risks.

The 12-month trial involved participants diagnosed with mild to moderate Alzheimer’s disease. According to the findings, the study did not achieve its primary objective, as the overall group of patients using the Spectris device did not exhibit a slower rate of cognitive decline compared to those who used an inactive, or sham, device.

Data provided by the study sponsor, Cognito Therapeutics, indicated that patients with moderate Alzheimer’s experienced no measurable benefit from the system. However, the results were more nuanced for those in the mild stages of the disease. The data suggested that participants with mild Alzheimer’s could experience a slower cognitive decline, particularly when the device was used nearly every day for close to the recommended 60-minute duration.

Christian Howell, the chief executive officer of Cognito Therapeutics, acknowledged the study’s failure to meet its primary endpoint but emphasized the potential for specific patient populations. “The signal we found in the mild population is really incredible,” Howell said in an interview, attributing the trial’s lack of overall success to the absence of a treatment effect in patients with moderate Alzheimer’s.

Despite the mixed outcomes, the company intends to move forward with a regulatory filing. “There is a very clear path for us to the F.D.A.,” Howell stated, signaling plans to seek approval from the Food and Drug Administration based on the findings observed in the mildly impaired population.

Evelyn Price

Evelyn Price covers health news, medical research, public health developments, and wellness topics. She aims to present evidence-based information in clear language, helping readers understand important studies, health policies, and advances in medicine.
Back to top button